NO20090605L - Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer - Google Patents

Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer

Info

Publication number
NO20090605L
NO20090605L NO20090605A NO20090605A NO20090605L NO 20090605 L NO20090605 L NO 20090605L NO 20090605 A NO20090605 A NO 20090605A NO 20090605 A NO20090605 A NO 20090605A NO 20090605 L NO20090605 L NO 20090605L
Authority
NO
Norway
Prior art keywords
respiratory depression
positive allosteric
ampa receptor
inhibition
receptor modulators
Prior art date
Application number
NO20090605A
Other languages
English (en)
Norwegian (no)
Inventor
John James Greer
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of NO20090605L publication Critical patent/NO20090605L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20090605A 2006-08-31 2009-02-10 Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer NO20090605L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82424506P 2006-08-31 2006-08-31
PCT/CA2007/001517 WO2008025148A1 (fr) 2006-08-31 2007-08-30 Procédé d'inhibition de la dépression respiratoire dans lequel sont utilisés des modulateurs allostériques positifs des récepteurs ampa

Publications (1)

Publication Number Publication Date
NO20090605L true NO20090605L (no) 2009-03-26

Family

ID=39135467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090605A NO20090605L (no) 2006-08-31 2009-02-10 Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer

Country Status (13)

Country Link
US (4) US8039468B2 (fr)
EP (1) EP2061471A4 (fr)
JP (1) JP2010501597A (fr)
KR (1) KR20090047534A (fr)
CN (1) CN101600436A (fr)
AU (1) AU2007291848B2 (fr)
BR (1) BRPI0716375A2 (fr)
CA (1) CA2660431C (fr)
IL (1) IL197334A0 (fr)
MX (1) MX2009002180A (fr)
NO (1) NO20090605L (fr)
WO (1) WO2008025148A1 (fr)
ZA (1) ZA200900955B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002180A (es) * 2006-08-31 2009-06-05 Univ Alberta Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa.
BRPI0823262A2 (pt) 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SG10202005916QA (en) 2015-12-22 2020-07-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (fr) 2018-05-11 2021-03-17 Zogenix International Limited Compositions et méthodes pour traiter la mort subite provoquée par la crise épileptique
EP3806835A1 (fr) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions et méthodes pour traiter la dépression respiratoire avec de la fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ255097A (en) 1992-07-24 2001-04-27 Univ California Heterocyclic derivatives (such as 1-(1,4-bgenzodioxan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine) and medicaments that enhance synaptic responses
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20030100552A1 (en) 2001-05-17 2003-05-29 Boehringer Ingelheim Pharma Kg Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions
DE10123952A1 (de) * 2001-05-17 2002-11-21 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CN1390543A (zh) * 2002-07-25 2003-01-15 湖南省岳阳市制药三厂 注射用奥拉西坦药品
EA200501117A1 (ru) * 2003-01-13 2006-02-24 Кортекс Фармасеутикалс, Инк. Способ лечения снижения когнитивной способности вследствие лишения сна и стресса
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
MX2009002180A (es) * 2006-08-31 2009-06-05 Univ Alberta Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa.

Also Published As

Publication number Publication date
MX2009002180A (es) 2009-06-05
CN101600436A (zh) 2009-12-09
US20120004219A1 (en) 2012-01-05
KR20090047534A (ko) 2009-05-12
BRPI0716375A2 (pt) 2013-10-15
US20160120873A1 (en) 2016-05-05
EP2061471A4 (fr) 2012-02-01
CA2660431C (fr) 2015-03-17
US20190030041A1 (en) 2019-01-31
IL197334A0 (en) 2009-12-24
US8039468B2 (en) 2011-10-18
US20080261962A1 (en) 2008-10-23
ZA200900955B (en) 2011-04-28
EP2061471A1 (fr) 2009-05-27
CA2660431A1 (fr) 2008-03-06
AU2007291848B2 (en) 2012-01-12
AU2007291848A1 (en) 2008-03-06
JP2010501597A (ja) 2010-01-21
WO2008025148A1 (fr) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20090605L (no) Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer
WO2007095091A3 (fr) Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
BRPI0818762A8 (pt) Composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição
MY146969A (en) Dpp iv inhibitor formulations
UA94964C2 (ru) Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
EA201101270A1 (ru) Циклические ингибиторы 11бета-гидроксистероид дегидрогеназы 1
DK2114383T3 (da) Små-volumen orale transmukosale doseringsformer indeholdende sufentanil til behandling af smerte
UA87841C2 (ru) Композиция, которая содержит амброксол, для местного применения
BRPI0515372B8 (pt) composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
SG169353A1 (en) Tamper resistant dosage forms
NO20084987L (no) Belagt farmasoytisk produkt for intraoral avlevering av nikotin innbefattende trometamol som bufringsmiddel
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ECSP088854A (es) Moduladores bencimidazolicos de vr1
MX2010003923A (es) Formulacion farmaceutica de valsartan.
BRPI0917661B8 (pt) produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
MX2010001243A (es) Composicion anti-inflamatoria.
EA201000926A1 (ru) Пиперазины в качестве агентов против ожирения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application